The appointment of former Novartis exec Fiona Milner will provide PharmAust’s subsidiary Epichem the leadership it needs to take the company to the next stage.

PharmAust’s (ASX:PAA) wholly owned subsidiary, Epichem, has bolstered its team following the appointment of a highly experienced pharmaceutical executive as its new General Manager.

Fiona Milner, who has 25 years of working in multinational companies within the industry under her belt, will take up the post effective on June 29.

Most recently, Milner was the Regional Sales Manager for Novartis Pharmaceuticals, where she held a number of roles within the last 14 years.

During that time, Milner received various recognitions including the International First Line Manager Award in 2011 and 2019 from Novartis’ Global CEO in Switzerland – one of only 35 staff to have been given this recognition globally.

Milner was also nominated for the ‘Telstra Business Woman of the Year’ Award in 2010 and 2011.

Sanofi experience

Prior to her role at Novartis, Milner was the State Manager at pharmaceutical company Sanofi Aventis, a role she held for 11 years.

During her tenure at Sanofi, she grew and led the Western Australia State branch in 2007 where she contributed a total of $56.4 million to the company’s national sales that year.

Milner received the Sanofi State of the Nation award six times, and was also awarded Manager of the Year.

“I’m excited to bring a dynamic and clear commitment to drive growth and performance for Epichem – leading through promoting diversity, harnessing change and embracing commercial opportunities,” Milner says of her appointment.

Meanwhile, PharmAust’s Executive Chairman Dr Roger Aston believes that Milner will take Epichem to the next level.

“We’re all delighted that Fi has decided to join Epichem,” Aston says.

“She has an outstanding record in driving performance and adding value, and we are confident that she will be able to grow and diversify the Epichem business and take the business to the next level of increased revenues and profitability,” he adds.

New business development manager

As part of that strategy, Epichem has also recently appointed a Business Development Manager, Ingrid Klopper.

Klopper’s extensive experience includes 10 years of technical sales and account management in B2B sales and business development.

She’s worked across a broad range of industries including life sciences, biotech, mining, industrial, agriculture, marine and construction.

It’s expected that Klopper will support Epichem’s strategy in business development, marketing, sales and social media to create and build long term business relationships.

Her responsibility will also include identifying new clients and projects across all five divisions of the Epichem business.

Epichem has been delivering products and services in synthetic and medicinal chemistry to the global pharmaceutical industry in over 40 countries for over 18 years.

The company owns newly constructed, purpose-built state-of-the-art laboratories, along with world class equipment and expertise to support new drug discovery projects.

In addition, Epichem’s e-waste project could create new revenue streams for PharmAust, as the company eyes the lucrative waste and mining industry.

Using its proprietary Oxidative Hydrothermal Dissolution (OHD) technology, the company could turn a wide range of waste and biomass feedstock into valuable products such as fuel.

This article was developed in collaboration with PharmAust, a Stockhead advertiser at the time of publishing.

This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.